Nicole Onetto
Director/Board Member at BOLT BIOTHERAPEUTICS, INC.
Net worth: 31 741 $ as of 2024-04-29
Profile
Dr. Nicole M.
Onetto, MD, is an Independent Director at Bolt Biotherapeutics, Inc. and an Independent Non-Executive Director at Basilea Pharmaceutica AG.
She is on the Board of Directors at CDR-Life Inc., Bolt Biotherapeutics, Inc. and Basilea Pharmaceutica AG.
Dr. Onetto was previously employed as an Independent Director by Viracta Therapeutics, Inc., an Independent Director by Sunesis Pharmaceuticals, Inc., an Independent Director by Sierra Oncology, Inc., a Deputy Director & Chief Scientific Officer by Ontario Institute for Cancer Research, a Chief Medical Officer & Senior Vice President by ZymoGenetics, Inc., an Independent Director by ImmunoGen, Inc., a Chief Medical Officer & Executive Vice President by OSI Pharmaceuticals, Inc., a Senior Vice President-Medical Affairs by Gilead Sciences, Inc., a Vice President-Medical Affairs by NeXstar Pharmaceuticals, Inc., and a Senior Director-Medical Affairs by Bristol Myers Squibb Co. She also served on the board at NBE-Therapeutics AG and YM BioSciences, Inc. She received her graduate degree from the University of Montréal.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
BASILEA PHARMACEUTICA AG
0.01% | 2022-12-30 | 737 ( 0.01% ) | 31 741 $ | 2024-04-29 |
2024-03-27 | 0 ( -.--% ) | - $ | 2024-04-29 |
Nicole Onetto active positions
Companies | Position | Start |
---|---|---|
BASILEA PHARMACEUTICA AG | Director/Board Member | 2017-04-26 |
BOLT BIOTHERAPEUTICS, INC. | Director/Board Member | 2021-12-13 |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | Director/Board Member | 2022-12-07 |
Former positions of Nicole Onetto
Companies | Position | End |
---|---|---|
VIRACTA THERAPEUTICS, INC. | Director/Board Member | 2023-06-07 |
VIRACTA THERAPEUTICS, INC. | Director/Board Member | 2021-01-31 |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Director/Board Member | 2020-12-31 |
SIERRA ONCOLOGY, INC. | Director/Board Member | 2019-11-21 |
IMMUNOGEN, INC. | Director/Board Member | 2016-12-08 |
Training of Nicole Onetto
University of Montréal | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 5 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
GILEAD SCIENCES, INC. | Health Technology |
BASILEA PHARMACEUTICA AG | Health Technology |
VIRACTA THERAPEUTICS, INC. | Health Technology |
BOLT BIOTHERAPEUTICS, INC. | Health Technology |
Private companies | 11 |
---|---|
OSI Pharmaceuticals, Inc.
OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
NeXstar Pharmaceuticals, Inc.
NeXstar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeXstar Pharmaceuticals, Inc. was a commercial biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious diseases. The firm was located in Boulder, CO. | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Ontario Institute for Cancer Research
Ontario Institute for Cancer Research Hospital/Nursing ManagementHealth Services Ontario Institute for Cancer Research provides research on the prevention, early detection, diagnosis, and treatment of cancer. It offers Innovation programs, like cancer stem cell, innovation in target validation, and smarter imaging, Technology programs, like drug discovery, genome technologies, informatics and bio-computing, imaging translation, and tranformative pathology, and Translation programs. The company was founded by Calvin R. Stiller in December 2005 and is headquartered in Toronto, Canada. | Health Services |
Université de Paris 5 René Descartes | Consumer Services |
Sierra Oncology, Inc.
Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
CDR-Life Inc.
CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | Health Technology |
- Stock Market
- Insiders
- Nicole Onetto